Brady W J, DeBehnke D J, Wickman L L, Lindbeck G
University of Virginia School of Medicine, Department of Emergency Medicine, Charlottesville, USA.
Acad Emerg Med. 1996 Jun;3(6):574-85. doi: 10.1111/j.1553-2712.1996.tb03467.x.
To compare the use of adenosine and the use of verapamil as out-of-hospital therapy for supraventricular tachycardia (SVT).
A period of prospective adenosine use (March 1993 to February 1994) was compared with a historical control period of verapamil use (March 1990 to February 1991) for SVT. Data were obtained for SVT patients treated in a metropolitan, fire-department-based paramedic system serving a population of approximately 1 million persons. Standard drug protocols were used and patient outcomes (i.e., conversion rates, complications, and recurrences) were monitored.
During the adenosine treatment period, 105 patients had SVT; 87 (83%) received adenosine, of whom 60 (69%) converted to a sinus rhythm (SR). Vagal maneuvers (VM) resulted in restoration of SR in 8 patients (7.6%). Some patients received adenosine for non-SVT rhythms: 7 sinus tachycardia, 18 atrial fibrilation, 7 wide-complex tachycardia (WCT), and 2 ventricular tachycardia; no non-SVT rhythm converted to SR and none of these patients experienced an adverse effect. Twenty-five patients were hemodynamically unstable (systolic blood pressure < 90 mm Hg), with 20 receiving drug and 13 converting to SR; 8 patients required electrical cardioversion. Four patients experienced adverse effects related to adenosine (chest pain dyspnea, prolonged bradycardia, and ventricular tachycardia). In the verapamil period, 106 patients had SVT: 52 (49%) received verapamil (p < 0.001, compared with the adenosine period), of whom 43 (88%) converted to SR (p = 0.11). Two patients received verapamil for WCT; neither converted to SR and both experienced cardiovascular collapse. VM resulted in restoration of SR in 12 patients (11.0%) (p = 0.52). Sixteen patients were hemodynamically unstable, with 5 receiving drug (p = 0.005) and 5 converting to SR; 9 patients required electrical cardioversion (p = 0.48). Four patients experienced adverse effects related to verapamil (hypotension ventricular tachycardia, ventricular fibrillation). Recurrence of SVT was noted in 2 adenosine patients and 2 verapamil patients in the out-of-hospital setting and in 23 adenosine patients and 15 verapamil patients after ED arrival, necessitating additional therapy (p = 0.48 and 0.88, for recurrence rates and types of additional therapies, respectively). Hospital diagnoses, outcomes, and ED dispositions were similar for the 2 groups.
Adenosine and verapamil were equally successful in converting out-of-hospital SVT in patients with similar etiologies responsible for the SVT. Recurrence of SVT occurred at similar rates for the 2 medications. Rhythm misidentification remains a common issue in out-of-hospital cardiac care in this emergency medical services system.
比较腺苷与维拉帕米作为院外治疗室上性心动过速(SVT)的疗效。
将1993年3月至1994年2月前瞻性使用腺苷的时期与1990年3月至1991年2月使用维拉帕米的历史对照时期用于SVT的治疗情况进行比较。数据来自于一个为约100万人口服务的、基于消防部门护理人员系统的大城市地区接受治疗的SVT患者。采用标准药物方案,并监测患者的治疗结果(即转复率、并发症和复发情况)。
在腺苷治疗期间,105例患者患有SVT;87例(83%)接受了腺苷治疗,其中60例(69%)转复为窦性心律(SR)。迷走神经手法(VM)使8例患者(7.6%)恢复为SR。一些患者因非SVT心律接受了腺苷治疗:7例窦性心动过速、18例心房颤动、7例宽QRS波心动过速(WCT)和2例室性心动过速;无非SVT心律转复为SR,且这些患者均未出现不良反应。25例患者血流动力学不稳定(收缩压<90 mmHg),20例接受了药物治疗,13例转复为SR;8例患者需要进行电复律。4例患者出现与腺苷相关的不良反应(胸痛、呼吸困难、心动过缓延长和室性心动过速)。在维拉帕米治疗期间,106例患者患有SVT:52例(49%)接受了维拉帕米治疗(与腺苷治疗期相比,p<0.001),其中43例(88%)转复为SR(p = 0.11)。2例患者因WCT接受了维拉帕米治疗;均未转复为SR,且均出现心血管虚脱。VM使12例患者(11.0%)恢复为SR(p = 0.52)。16例患者血流动力学不稳定,5例接受了药物治疗(p = 0.005),5例转复为SR;9例患者需要进行电复律(p = 0.48)。4例患者出现与维拉帕米相关的不良反应(低血压、室性心动过速、心室颤动)。在院外环境中,2例腺苷治疗患者和2例维拉帕米治疗患者出现SVT复发,在急诊科就诊后,23例腺苷治疗患者和15例维拉帕米治疗患者出现复发,需要进一步治疗(复发率和额外治疗类型的p值分别为0.48和0.88)。两组患者的医院诊断、治疗结果和急诊科处置情况相似。
对于病因相似的院外SVT患者,腺苷和维拉帕米在转复方面同样成功。两种药物的SVT复发率相似。在这个紧急医疗服务系统中,院外心脏护理中节律误判仍然是一个常见问题。